Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2008-09-10
2009-11-03
Lewis, Patrick T (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S046000, C514S047000, C514S048000, C514S049000, C514S050000, C514S051000, C536S026200, C536S026230, C536S026260
Reexamination Certificate
active
07612047
ABSTRACT:
The present invention relates to mononucleoside phosphate compounds that have the benefits of a dinucleotide pharmaceutical. These mononucleoside phosphates can be made from a mononucleotide that has been modified by attaching a degradation-resistant substituent on the terminal phosphate of a polyphosphate mononucleotide. By attaching this degradation-resistant substituent, the stability from degradation matches or exceeds those of certain dinucleotides. The mononucleoside phosphate compounds of the present invention are useful in preventing and treating epithelial tissue diseases or diseases or disorders associated with platelet aggregation.
REFERENCES:
patent: 3321463 (1967-05-01), Moffatt
patent: 5292498 (1994-03-01), Boucher, Jr.
patent: 5628984 (1997-05-01), Boucher, Jr.
patent: 5635160 (1997-06-01), Stutts, III et al.
patent: 5654285 (1997-08-01), Ingall et al.
patent: 5721219 (1998-02-01), Ingall et al.
patent: 5747496 (1998-05-01), Cox et al.
patent: 5837861 (1998-11-01), Pendergast et al.
patent: 5900407 (1999-05-01), Yerxa et al.
patent: 5955447 (1999-09-01), Ingall et al.
patent: 6166022 (2000-12-01), Brown et al.
patent: 6319908 (2001-11-01), Yerxa et al.
patent: 6323187 (2001-11-01), Yerxa et al.
patent: 7018985 (2006-03-01), Boyer et al.
patent: 7115585 (2006-10-01), Yerxa et al.
patent: 7132408 (2006-11-01), Boyer et al.
patent: 7435724 (2008-10-01), Douglass et al.
patent: WO 92/17488 (1992-10-01), None
patent: WO 94/18216 (1994-08-01), None
patent: WO 97/03084 (1997-01-01), None
patent: WO 98/28300 (1998-07-01), None
patent: WO 00/33080 (2000-06-01), None
patent: WO 00/34283 (2000-06-01), None
patent: WO 01/19826 (2001-03-01), None
patent: WO 01/36421 (2001-05-01), None
patent: WO 01/39781 (2001-06-01), None
patent: WO 03/072067 (2003-09-01), None
Abbracchio and Burnstock, “Purinergic Signalling: Pathophysiological Roles,”Jpn J. Pharmacol, 78:113-120 (1998).
Brown, et al., “Evidence that UTP and ATP Regulate Phospholipase C through a Common Extracellular 5'-Nucleotide Receptor in Human Airway Epithelial Cells,”Mol. Pharmocol. 40:648-55 (1991).
Drutz, et al., “Uridine 5' Triphosphate (UTP) Regulates Mucociliary Clearance via Purinergic Receptor Activation,”Drug Dev. Res. 37(3):185 (1996).
Gobran, “P2u purinoceptor stimulation of surfactant secretion coupled to phosphatidylcholine hydrolysis in type II cells,”Am. J. Physiol. 267:L625-L633 (1994).
Letham, M., et al., “Nucleotide Regulation of Goblet Cells in Human Airway Epithelial Explants: Normal Exocytosis in Cystic Fibrosis,”Am. J. Respir. Cell Mol. Biol. 9:315-22 (1993).
Mason, S., et al. “Regulation of transepithelial ion transport and intracellular calcium by extracellular ATP in human normal and cystic fibrosis airway epithelium,”Br. J. Pharmacol. 103:1649-56 (1991).
Moffatt et al., “Nucleoside polyphosphates . . . ”, Journal of the American Chemical Society 80, 3756-61, 1958.
Schwartz, “Current Concepts in Ophthamology,”N.Engl. J. Med., 290:182-186 (1978).
Yerxa, et al.,Drugs of the Future, 24:759-769 (1999).
Boyer José L.
Brown Edward G.
Crean Christopher S.
Douglass, III James G.
Peterson Ward M.
Howrey LLP
Inspire Pharmaceuticals Inc.
Kung Viola T.
Lewis Patrick T
LandOfFree
Degradation-resistant mononucleoside phosphate compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Degradation-resistant mononucleoside phosphate compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Degradation-resistant mononucleoside phosphate compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4073853